{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T11:23:08Z","timestamp":1769253788541,"version":"3.49.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Little is known about the distribution of posaconazole in brain tissue and CSF. We therefore analysed trough concentrations of posaconazole in paediatric leukaemia patients in non-inflamed CSF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>The study included paediatric patients &amp;lt;18 years of age with acute leukaemia in remission who underwent repeat therapeutic lumbar punctures as part of their anti-leukaemia treatment. CSF and blood were obtained 20\u201324 h after dosing, and posaconazole was measured by LC-MS\/MS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six patients (median age: 10 years; range, 6\u201314) with acute lymphatic (three) or acute myeloid (three) leukaemia were included who received posaconazole gastroresistant tablets at weight-banded doses (five) or the oral solution (one). In contrast to 14 control samples, posaconazole was detectable in all 11 samples of treated patients. CSF concentrations ranged from 8.3 to 42 ng\/mL with a median CSF concentration of 13.6 ng\/mL. Concurrent serum concentrations were between 965 and 5177 ng\/mL with a median of 1716 ng\/mL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Trough concentrations of posaconazole in the CSF after systemic administration were low but detectable in all subjects. Concurrent serum concentrations were in the target range for prophylaxis and treatment in 100% and 90%, respectively.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae005","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T19:07:46Z","timestamp":1704913666000},"page":"564-566","source":"Crossref","is-referenced-by-count":2,"title":["Cerebrospinal fluid concentrations of posaconazole in paediatric leukaemia patients"],"prefix":"10.1093","volume":"79","author":[{"given":"Katharina","family":"K\u00f6rholz","sequence":"first","affiliation":[{"name":"Center for Bone Marrow Transplantation and Department of Pediatric Hematology and Oncology, Infectious Disease Research Program, University Children\u00b4s Hospital M\u00fcnster , M\u00fcnster , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Holterhus","sequence":"additional","affiliation":[{"name":"Center for Bone Marrow Transplantation and Department of Pediatric Hematology and Oncology, Infectious Disease Research Program, University Children\u00b4s Hospital M\u00fcnster , M\u00fcnster , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Gordon","sequence":"additional","affiliation":[{"name":"Center for Bone Marrow Transplantation and Department of Pediatric Hematology and Oncology, Infectious Disease Research Program, University Children\u00b4s Hospital M\u00fcnster , M\u00fcnster , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"M\u00fcller-Ohrem","sequence":"additional","affiliation":[{"name":"TDM-Laboratory, Pharmacology at the Laboratory Diagnostic Center, University Hospital of Cologne , Cologne , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"TDM-Laboratory, Pharmacology at the Laboratory Diagnostic Center, University Hospital of Cologne , Cologne , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-393X","authenticated-orcid":false,"given":"Andreas H","family":"Groll","sequence":"additional","affiliation":[{"name":"Center for Bone Marrow Transplantation and Department of Pediatric Hematology and Oncology, Infectious Disease Research Program, University Children\u00b4s Hospital M\u00fcnster , M\u00fcnster , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"2024030105173364200_dkae005-B1","doi-asserted-by":"crossref","first-page":"e29275","DOI":"10.1002\/pbc.29275","article-title":"Invasive fungal disease in children with acute myeloid leukaemia: an Australian multicentre 10-year review","volume":"68","author":"Yeoh","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2024030105173364200_dkae005-B2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41375-022-01768-x","article-title":"Invasive fungal diseases impact on outcome of childhood ALL\u2014an analysis of the international trial AIEOP-BFM ALL 2009","volume":"37","author":"Lehrnbecher","year":"2023","journal-title":"Leukemia"},{"key":"2024030105173364200_dkae005-B3","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024030105173364200_dkae005-B4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/FTD.0000000000000438","article-title":"Reliable and easy-to-use liquid chromatography-tandem mass spectrometry method for simultaneous analysis of fluconazole, isavuconazole, itraconazole, hydroxy-itraconazole, posaconazole, and voriconazole in human plasma and serum","volume":"39","author":"M\u00fcller","year":"2017","journal-title":"Ther Drug Monit"},{"key":"2024030105173364200_dkae005-B5","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1093\/jac\/dkz359","article-title":"Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents","volume":"74","author":"Tragiannidis","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024030105173364200_dkae005-B6","doi-asserted-by":"crossref","first-page":"e0212837","DOI":"10.1371\/journal.pone.0212837","article-title":"A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia","volume":"14","author":"Arrieta","year":"2019","journal-title":"PLoS One"},{"key":"2024030105173364200_dkae005-B7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure\u2013response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2024030105173364200_dkae005-B8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40272-013-0017-5","article-title":"Pharmacokinetics of antibacterial agents in the CSF of children and adolescents","volume":"15","author":"Sullins","year":"2013","journal-title":"Paediatr Drugs"},{"key":"2024030105173364200_dkae005-B9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.01558-13","article-title":"A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid","volume":"58","author":"Wiederhold","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024030105173364200_dkae005-B10","doi-asserted-by":"crossref","first-page":"e01184-19","DOI":"10.1128\/AAC.01184-19","article-title":"Low central nervous system posaconazole concentrations during cerebral phaeohyphomycosis","volume":"63","author":"Barde","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024030105173364200_dkae005-B11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/myc.12892","article-title":"Antifungal susceptibility of yeast bloodstream isolates collected during a 10-year period in Austria","volume":"62","author":"Beyer","year":"2019","journal-title":"Mycoses"},{"key":"2024030105173364200_dkae005-B12","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1093\/jac\/dkaa212","article-title":"Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators","volume":"75","author":"J\u00f8rgensen","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024030105173364200_dkae005-B13","doi-asserted-by":"crossref","first-page":"e00906-17","DOI":"10.1128\/AAC.00906-17","article-title":"Monitoring antifungal resistance in a global collection of invasive yeasts and molds: application of CLSI epidemiological cutoff values and whole-genome sequencing analysis for detection of azole resistance in Candida albicans","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024030105173364200_dkae005-B14","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1128\/AAC.48.10.4063-4066.2004","article-title":"Efficacy of posaconazole in a murine model of central nervous system aspergillosis","volume":"48","author":"Imai","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024030105173364200_dkae005-B15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/jof6010033","article-title":"Posaconazole alone and in combination with caspofungin for treatment of experimental Exserohilum rostratum meningoencephalitis: developing new strategies for treatment of phaeohyphomycosis of the central nervous system","volume":"6","author":"Petraitiene","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2024030105173364200_dkae005-B16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/jac\/dki288","article-title":"Activity of posaconazole in the treatment of central nervous system fungal infections","volume":"56","author":"Pitisuttithum","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2024030105173364200_dkae005-B17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2174\/157016212803305970","article-title":"Meningitis due to Cryptococcus neoformans: treatment with posaconazole","volume":"10","author":"Flores","year":"2012","journal-title":"Curr HIV Res"},{"key":"2024030105173364200_dkae005-B18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024030105173364200_dkae005-B19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J Infect Dis"},{"key":"2024030105173364200_dkae005-B20","doi-asserted-by":"crossref","first-page":"e01626-19","DOI":"10.1128\/AAC.01626-19","article-title":"Amphotericin B penetrates into the central nervous system through focal disruption of the blood brain barrier in experimental hematogenous Candida meningoencephalitis","volume":"63","author":"Petraitis","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024030105173364200_dkae005-B21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1086\/524063","article-title":"The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates","volume":"197","author":"Hope","year":"2008","journal-title":"J Infect Dis"},{"key":"2024030105173364200_dkae005-B22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-4453(96)92700-0","article-title":"Trends in the postmortem epidemiology of invasive fungal infections at a university hospital","volume":"33","author":"Groll","year":"1996","journal-title":"J Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/3\/564\/56796820\/dkae005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/3\/564\/56796820\/dkae005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T05:19:27Z","timestamp":1709270367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/3\/564\/7514597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,10]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae005","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,1,10]]}}}